Abciximab improves the outcome with coronary artery stenting

Data from the EPISTENT trial of 2399 patients undergoing emergent or elective angioplasty. Top panel: The 30-day incidence of the primary endpoint (death, MI, or need for urgent revascularization) was significantly lower among patients receiving a stent with abciximab compared to those undergoing angioplasty with abciximab therapy or stenting alone (5.3, 6.9, and 10.8 percent, respectively). Bottom panel: The benefit from abciximab primarily reflected a reduced incidence of death and of large non-Q wave MI (shown in blue).